PTGX
Protagonist Therapeutics, Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Protagonist Therapeutics, Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
+6.45%
vs ±11.8% implied · ×0.55
shaded = implied · ▲▼ = realized
Protagonist Therapeutics, Inc
144.17
Linked news
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Protagonist Therapeutics, Inc's 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Protagonist Therapeutics, Inc's 6 closest co-movers, none share that code.
—
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $1.3B | 13.49% | +5.40% |
| Farallon | $778.2M | 8.31% | 0.00% |
| RTW | $620.4M | 6.62% | +0.04% |
| Vanguard Portfolioindex-like | $444.9M | 4.75% | +4.25% |
| Wellington | $418.8M | 4.47% | −5.08% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $1.3B | 13.49% | +5.40% |
| Farallon | $778.2M | 8.31% | 0.00% |
| RTW | $620.4M | 6.62% | +0.04% |
| Vanguard Portfolioindex-like | $444.9M | 4.75% | +4.25% |
| Wellington | $418.8M | 4.47% | −5.08% |
Bull1
Bear2
Expected move
Inputs8Q avg ±3.1%·×1.81·rich
straddle ±7.7%
spot 144.85exp Nov 20ATM strike 145ATM straddle 13.20IV 48%